Evidence map›Paper›PMID 22417684›Full record

ArticleThe Biochemical journal2012

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.

Kylie M Wagstaff, Haran Sivakumaran, Steven M Heaton, David Harrich, David A Jans

4 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 381 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
381citing papers in PubMed, 6 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04391127 phase3completednot on this mapstarted 2020, after this paper: background citation

Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial

TypeinterventionalSponsorCentenario Hospital Miguel HidalgoRan2020 to 2020Enrolled108ConditionsCOVID-19ArmsHydroxychloroquine, Ivermectin, Placebo
NCT04529525 phase2 / phase3completednot on this mapstarted 2020, after this paper: background citation

Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled

TypeinterventionalSponsorInstituto de Cardiología de CorrientesRan2020 to 2021Enrolled501ConditionsCovid19ArmsIvermectin, Placebo
NCT04595136 phase1 / phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

A Two-arm Randomized Double-blind Study With COVID19-0001-USR Administered Via Nebulization to Patients With Mild and/or Moderate Severe Acute Respiratory Syndrome (SARS-COV-2) Infection to Decrease Viral Load

TypeinterventionalSponsorUnited Medical SpecialtiesRan2020 to 2021Enrolled60ConditionsSARS-CoV-2 InfectionArmsDrug COVID19-0001-USR, normal saline
NCT04602507 phase2terminatednot on this mapstarted 2020, after this paper: background citation

Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial

TypeinterventionalSponsorCES UniversityRan2020 to 2021Enrolled75ConditionsCovid19, Severe Acute Respiratory SyndromeArmsIvermectin, Placebo
3 · Its place in the literature

Who cites it

381 citing papers in PubMed, 6 syntheses or guidelines pooled it, 672 citations in OpenAlex.

  1. Pooled it
  2. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  6. Pooled it
  7. Trial
  8. The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 - a double-blind, randomized placebo-controlled trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Trial
  9. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2021
    Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

321 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kylie M WagstaffNuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
Haran Sivakumaran
Steven M Heaton
David Harrich
David A Jans
Monash University · AUQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The movement of proteins between the cytoplasm and nucleus mediated by the importin superfamily of proteins is essential to many cellular processes, including differentiation and development, and is critical to disease states such as viral disease and oncogenesis. We recently developed a high-throughput screen to identify specific and general inhibitors of protein nuclear import, from which ivermectin was identified as a potential inhibitor of importin α/β-mediated transport. In the present study, we characterized in detail the nuclear transport inhibitory properties of ivermectin, demonstrating that it is a broad-spectrum inhibitor of importin α/β nuclear import, with no effect on a range of other nuclear import pathways, including that mediated by importin β1 alone. Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively. Ivermectin would appear to be an invaluable tool for the study of protein nuclear import, as well as the basis for future development of antiviral agents.

Indexed as

Dengue VirusHeLa CellsHIV-1HumansIvermectinKaryopherinsVirus ReplicationIvermectinKaryopherins

Identifiers

PMID22417684
PMCPMC3327999
OpenAlexW1965936780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.